- Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar. Barron’s
- There’s a New Obesity King The Wall Street Journal
- An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment CNN
- Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps CNBC
- Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results Yahoo Finance
Powered by WPeMatico